Kornimate/medical-research-clean huggingface dataset:
orelabrutinib followed by response-adapted ultra-low dose 4gy radiation as first-line treatment of malt lymphoma

Conditions: Lymphoma, B-Cell, Marginal Zone

Summary: investigate the efficacy and safety of orelabrutinib followed by response-adapted ultra-low dose 4gy radiation in the treatment of local-stage malt lymphoma

this prospective, multicenter trial is trying to evaluate the efficacy and safety of orelabrutinib followed by response-adapted ultra-low dose 4gy radiation as first-line treatment of local-stage mucosa associated lymphoid tissue extranodal marginal zone lymphoma

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * histologically confirmed mucosa-associated lymphoid tissue (malt) lymphoma * lugano stage i-ii * ecog 0-2 * signed informed consent * having sufficient organ function: a) hematopoietic function: neutrophils ≥ 1.0 × 109/l, plt ≥ 50 × 109/l, hb ≥ 80g/l; b) liver function: bilirubin ≤1.5 times the upper limit of normal (uln), alt and ast\<3 x uln, serum albumin ≥ 30 g/l; c) renal function: serum cr\<1.5 × uln, creatinine clearance rate ≥ 50ml/min (calculated according to the standard cockcroft gault formula, if renal dysfunction is caused by tumor compression, creatinine clearance rate ≥ 30ml/min); d) coagulation function (unless the subject is receiving anticoagulant therapy and the coagulation parameters (pt/inr and aptt) are within the expected range of anticoagulant therapy at the time of screening): international standardized ratio (inr) ≤ 1.5 x uln; activated partial thromboplastin time (aptt) ≤ 1.5 x uln. exclusion criteria: * recent major surgery (within 4 weeks prior to enrollment), except for diagnostic surgery * have uncontrolled intercurrent diseases (cardiovascular and cerebrovascular diseases, coagulation disorders, severe infectious diseases) including but not limited to: severe acute or chronic infection requiring systemic treatment, symptomatic congestive heart failure (nyha iii-iv) or symptomatic or poorly controlled arrhythmias, arterial hypertension (systolic blood pressure ≥ 160mmhg or diastolic blood pressure ≥100mmhg) that is not controlled even with standard treatment, unstable angina, active peptic ulcer or bleeding disorder; * severe concomitant diseases that interfere with treatment * active interstitial pneumonia * active chronic hepatitis b infection (defined as hbv dna positive; patients with latent or prior hepatitis b infection (defined as positive for hepatitis b surface antigen or hepatitis b core total antibody) can be included if hbv-dna is undetectable at screening. the above-mentioned patients must voluntarily undergo regular dna tests and receive appropriate antiviral therapy as prescribed) * positive hepatitis c test result (for patients who are positive for hcv antibodies, only polymerase chain reaction (pcr) shows a negative hcv rna can participate) * patients with active hiv and syphilis infections; * pregnant or lactating women * patients with multiple factors affecting oral medication (such as dysphagia, nausea, vomiting, chronic diarrhea, and intestinal obstruction) * the researcher determined that patients are not suitable to participate in this study.
safety and efficacy of tsha-102 in pediatric females with rett syndrome (reveal pediatric study)

Conditions: Rett Syndrome

Summary: the reveal pediatric study is a multi-center, phase 1/2 open-label, dose-escalation and dose-expansion study of tsha-102, an investigational gene therapy, in pediatric females with rett syndrome. the safety, tolerability, and preliminary efficacy of two dose levels will be evaluated. the study duration is up to 6 years.


Eligibility criteria:
inclusion criteria: * participant has a confirmed diagnosis of classical/typical rett syndrome with a documented mutation of the mecp2 gene that results in loss of function. * participant is between ≥5 to ≤8 years of age at the time of consent. * participant must be up to date with all relevant local vaccination requirements, with last vaccination dose received at least 42 days prior to the start of the immunosuppression regimen. * participant's parent/caregiver must be willing to allow participant to receive blood or blood products for the treatment of an ae if medically needed. exclusion criteria: * participant has another neurodevelopmental disorder independent of the mecp2 gene loss of function mutation, or any other genetic syndrome with a progressive course. * participant has a history of brain injury that causes neurological problems. * participant had grossly abnormal psychomotor development in the first 6 months of life. * participant has a diagnosis of atypical rett syndrome. * participant has an mecp2 mutation that does not cause rett syndrome. * participant requires non-invasive and invasive ventilatory support. * participant has contraindications for it administration of tsha-102 or lumbar puncture procedure, other medical conditions, or contraindications to any medications required for it administration. * participant has acute or chronic hepatitis b or c infections.

Keywords: rett syndrome neurodevelopmental disorder mecp2
spinal mobilization with arm movement and positional snags in cervical radiculopathy patients

Conditions: Radiculopathy, Cervical

Summary: data will be collected in hussain memorial hospital by taking informed consent. randomised clinical trial is conducted taking thirty patients of both genders with confirmed diagnoses of cervical radiculopathy, their ages ranged from 25 to 60. a cluster of winner to rule out patient with cervical radiculopathy. they will be randomly assigned into two groups by the lottery method. group a will receive conventional treatment and of spinal mobilization with arm movement (intervention 1) group b will receive conventional treatment and positional snags (intervention 2). the treatment will be conducted at a frequency of three sessions per week for four weeks. two values will be taken, one as baseline and the other at end of the session. then follow up the patient to rule out which intervention is more effective than the other. neck disability index, numeric pain rating scale and rom will be used to measure outcomes.

the objective of the study is to compare the effect of spinal mobilization with arm movement and positional snags on pain and disability in cervical radiculopathy patients. the study design will be randomized clinicaltrial the sampling technique will be consecutive sampling technique tool: the neck disability index (ndi): used for measuring functional improvement in the neck. numeric pain rating scale (nprs): used for measuring pain. inclinometer: used for measuring range of motion of cervical region. data will be collected in hussain memorial hospital by taking informed consent. randomised clinical trial is conducted taking thirty patients of both genders with confirmed diagnoses of cervical radiculopathy, their ages ranged from 25 to 60. a cluster of winner criteria will be used to rule out patient with cervical radiculopathy. they will be randomly assigned into two groups by the lottery method. group a will receive conventional treatment and of spinal mobilization with arm movement (intervention 1) group b will receive conventional treatment and positional snags (intervention 2). the treatment will be conducted at a frequency of three sessions per week for four weeks. two values will be taken, one as baseline and the other at end of the session. then follow up the patient to rule out which intervention is more effective than the other. neck disability index, numeric pain rating scale and rom will be used to measure outcomes.

Eligibility criteria:
inclusion criteria * symptoms duration more than 6 months. * age 25 -60 * the patient has confirm the diagnosis of radiculopathy of cervical origin, * vas more than 5 * a cluster of wainner 3 positive out of 4 exclusion criteria * malignancy * infection (such as osteomyelitis or diskettes) * osteoporosis * inflammatory arthritis * fracture * pregnancy * uncontrolled hypertension or cardiovascular disease * carotid or vertebral artery disease. * trauma cases
epstein-barr virus (ebv)-specific t cells as therapy for relapsed/refractory ebv-positive lymphomas

Conditions: Lymphoma

Summary: this trial will use a new method of treating lymphoma using a therapy derived from a person's killer t cells. these killer t cells are taken from a person's blood and grown in a test tube to increase the number of these cells that are specifically active against the lymphoma cells. the cells are then given to the patient by intravenous infusion with the aim of killing the lymphoma cells. potentially this treatment will help to kill the residual/recurrent tumour that is present after other lymphoma treatment and reduce the chance of the tumour recurring.


Eligibility criteria:
inclusion criteria: * informed consent. * ebv-positive lymphoma as determined by in situ hybridization or equivalent (excluding burkitts lymphoma). * age 18 years or older. * ecog performance status 1, 2 or 3 * life expectancy of at least 6 months. * measurable disease: either relapsing, partially responsive, refractory or progressive disease, includes disease detected either by clinical examination, radiographic evaluation (including ct scans, and at physician's discretion by functional imaging), or a persistently detectable plasma ebv viral load. * no chemotherapy / radiotherapy and/or antibody therapy for at least 2 weeks prior to anticipated date of first infusion. exclusion criteria: * ebv negative tumour * presence of detectable malignant cells in the peripheral circulation by flow cytometry or morphology * serious infection within the past 28 days that has not adequately responded to therapy * pregnancy, or unwilling to use adequate contraception * serology (taken within 3 months of ctl release date) indicating active hbv or hcv infection, positive serology for hiv i\&ii, htlv1 or syphilis * negative serology for ebv * psychiatric, addictive or any condition which may compromise the ability to participate in this trial

Keywords: epstein-barr virus lymphoma immunotherapy
evaluation of a brachytherapy discharge education program to improve patient care

Conditions: Gynecologic Cancer

Summary: although brachytherapy is an effective treatment modality for gynecological cancer, a significant proportion of patients develop late treatment-related vaginal toxicity, negatively impacting their quality of life and limiting recurrent disease detection by preventing adequate clinical examination during the post-treatment surveillance period. consistent with the literature, results from a study at princess margaret revealed that current vaginal toxicity management education and training may be inadequate. the investigators seek to implement and evaluate a new online brachytherapy discharge education program (brachdep) to support patient engagement in self-management.

background: brachytherapy is a type of radiation therapy used to treat patients with gynecological cancers. brachytherapy delivers radiation to cancerous tissue by inserting or placing the radiation next to the target tissue. a common side effect that develops as a result of repeated brachytherapy is fibrosis, a thickening and hardening of tissue, as well as narrowing of the vagina, known as vaginal stenosis. to reduce the impact of vaginal stenosis, vaginal dilation is recommended upon discharge of brachytherapy. vaginal dilation involves the insertion of a smooth plastic tube into the vagina 3 to 4 times per week. despite the benefits of vaginal dilation, use of vaginal dilators is low among patients following brachytherapy. this poor adherence to vaginal dilator use may be due to embarrassment, discomfort, and lack of awareness of the benefits to patients. objective: the primary objective of this study is to evaluate the whether an online brachytherapy discharge education program increases patient satisfaction with education and care. secondary objectives are to determine whether the online education program increases patient quality of life, improves vaginal dilator compliance and reduces rates of vaginal stenosis post-treatment. methods: the research team will use a randomized, controlled trial study design. the impact of the online education program will be identified by comparing the outcomes of participants in the intervention arm against those patients in the control arm. participants will be recruited and randomized to one of two arms that will determine whether they will receive the education intervention. significance the results from this study will be used to improve the brachytherapy discharge education program.

Eligibility criteria:
inclusion criteria: * scheduled to receive brachytherapy for treatment of gynecologic cancer at princess margaret cancer centre. * able to provide written informed consent * able to read and write in english * \> 18 years of age exclusion criteria: * not receiving brachytherapy treatment

Keywords: brachytherapy vaginal stenosis vaginal toxicity online education health literacy
effects of aerobic thai dance in patient with diabetic peripheral neuropathy

Conditions: Exercise Addiction; Diabetic Neuropathies

Summary: the goal of this type of study is clinical trial. this to learn about effects of applied aerobic thai dance exercise on gait balance and sudomotor function in patient with diabetic peripheral neuropathy. test variables of gait, balance, function of sudomotor, physiological data such as pulse, blood pressure, body composition, ankle and leg muscle strength, compare with control and experimental group in diabetes with peripheral neuropathy. the main question question 1: dose applied aerobic thai dance exercise affects gait and balance in diabetic patients with peripheral neuropathy? question 2: does applied aerobic thai dance exercise affect sudomotor function in diabetic patients with peripheral neuropathy? participants will divided into 2 groups: the control group and the experimental group. by randomly sampling 22 people from each group 1. the control group was advised to exercise at home for a period of 12 weeks. 2. the experimental group participated in applied aerobic thai dance exercise 60 minutes per session, 3 times per week, for a period of 12 weeks. after 12 weeks, variable data were collected and to compare within and between groups.


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes between the ages of 60 and 75. * the bmi index is between 18.5 - 29.9 kg/m2. * mnsi score between 2.5 - 7.5 points. * there were no exercise-related complications from the par -q assessment. * light to moderate level of physical activity. * not being a person with severe optic neuropathy (severe-npdr and severe-pdr). * no wounds or infections on the feet. * no musculoskeletal abnormalities. * not being a pacemaker implantation person, no history of heart failure, evaluated new york heart association classification (nyha) not over functional class ii, if cad must be treated, no history of atrial fibrillation severely wrong. * the doctor did not have a plan to adjust the medication in the last 3 months. exclusion criteria: * mnsi score greater than or equal to 8 points or more. * participants lacked more than 20 percent of their exercise program. * participants had foot ulcers and infections during the experiment. * vitamins b1, 6 and 12 were taken during the trial. * the subject withdrew from the experiment.

Keywords: diabetes mellitus diabetic peripheral neuropathy thai dance gait balance sudomotor function dpn exercise
acute kidney injury in neonates at nicu in assiut university children hospital descriptive study

Conditions: Neonatal Acute Kidney Injury

Summary: acute kidney injury (aki) is a complex disorder with clinical manifestations ranging from mild dysfunction to complete anuric kidney failure. its leads to sudden and rapid decline in renal excretory function within hours to days,accompanied by accumulation of nitrogenous waste products such creatinine,urea and other clinically un measured products

acute kidney injury (aki) is an under-recognized morbidity of neonates; the incidence remains unclear due to the absence of a unified definition of aki in this population and because previous studies have varied greatly in screening for aki with serum creatinine and urine output assessments. premature infants may be born with less than half of the nephrons compared with term neonates, predisposing them to chronic kidney disease (ckd) early on in life and as they age. aki can also lead to ckd, and premature infants with aki may be at very high risk for long-term kidney problems. aki in neonates is often multifactorial and may result from prenatal, perinatal, or postnatal insults as well as any combination thereof.

Eligibility criteria:
inclusion criteria: * all cases of acute kidney injury in neonates who will be admitted to nicu assiut university children hospital during the duration of the study. exclusion criteria: * cases with chronic renal affection any case with congenital anomalies
oravescent fentanyl (ovf) for the treatment of breakthrough pain in opioid tolerant cancer patients

Conditions: Pain; Cancer

Summary: the purpose of this study is to evaluate the long-term safety and efficacy of oravescent fentanyl to treat breakthrough pain episodes in cancer patients who are already opioid tolerant.

the objective of this study is to determine the tolerability and safety of oravescent fentanyl when used long term to relieve breakthrough pain in opioid tolerant cancer patients.

Eligibility criteria:
inclusion criteria: * 18-80 years of age * average of 1-4 breakthrough pain episodes per day * opioid tolerant * histologically documented diagnosis of a malignant solid tumor or hematological malignancy exclusion criteria: * primary breakthrough pain is not related to cancer in any way * opioid or fentanyl intolerance * chronic obstructive pulmonary disease (copd) or heart disease * sleep apnea or active brain metastases with increased cranial pressure

Keywords: cancer pain
naturalistic sleep assessed by wearable devices in parkinson disease

Conditions: Parkinson Disease

Summary: the cardinal motor features of parkinson's disease (pd) include bradykinesia, rest tremor, and rigidity. though non-motor features have been recognized for centuries, only recently has the prevalence and impact of non-motor symptoms become the focus of intense study. disturbances of sleep are among the most common non-motor manifestations of pd; approximately two-thirds of pd patients experience sleep dysfunction of some kind. given that sleep contributes to the regulation of many physiological processes, sleep disturbance has a significant impact on quality of life in pd, and places high strain on caregivers. though numerous symptomatic therapies exist, the treatment of sleep disorders in pd is limited by a lack of adequately powered, randomized studies providing high quality evidence. although deep brain stimulation (dbs) is primarily used to treat pd motor symptoms and reduce the need for dopaminergic medications, several studies have shown that dbs provides benefit for non-motor symptoms, including sleep disturbance. few studies have used an objective measure to assess the impact of dbs on sleep in pd, and none have done so by studying sleep in the home environment. existing studies have largely been limited to a single night of sleep recording in a sleep lab. furthermore, no studies have assessed sleep both on and off medication, before and after dbs implantation. this study will enroll patients undergoing evaluation for dbs implantation. sleep will be assessed before dbs implantation, both while patients continue their usual medication regimen and while withholding medications. after dbs implantation and programming, sleep will again be assessed with stimulation on, both while continuing medications and subsequently while withholding medications.


Eligibility criteria:
inclusion criteria: research subjects must be willing and able to do the following: * be able to learn to use and maintain a wristband-style sleep monitor * wear a wristband-style sleep monitor for two weeks * be able to learn to use and maintain a headband sleep monitor * wear a headband sleep monitor for two weeks * log daily routine events, such sleeping, eating, and medication regimens for the two-week study period * withhold dopaminergic medications after 5:00pm for three consecutive nights exclusion criteria: subjects will be excluded if they: * carry a diagnosis of dementia (e.g., parkinson's disease dementia or dementia with lewy bodies) * currently use or recently (within past 30 days) used a sedative-hypnotic agent for sleep (e.g., zolpidem, suvorexant, eszopiclone) * fulfill criteria or carry a diagnosis of a circadian sleep-wake rhythm disorder, as defined by the international classification of sleep disorders, third edition
prostate cancer patients treated with alternative radiation oncology strategies

Conditions: Prostate Cancer

Summary: as the most common male carcinoma, prostate cancer is a major tumor entity in oncology. in addition to definitive radiotherapy, surgical procedure is considered to be an oncologically equivalent therapeutic alternative for non-metastatic malignancies in the primary setting. however, a subsequent radiotherapy of the prostate bed is often necessary, which takes place as an "adjuvant" treatment immediately after surgery or in the course of a repeated increase in psa and usually extends over several weeks. for the primary situation (without previous surgery), several randomized phase iii clinical trials have shown that it is possible to shorten radiotherapy by increasing the single dose (called hypofractionation). in the context of two prospective phase ii studies, which were carried out in heidelberg, it has since been shown that hypofractionation with both photons and protons is safe and feasible even in the postoperative situation. the current, prospective and randomized paros study is now intended to demonstrate a multicentric phase iii study as an improvement in the quality of life caused by rectum toxicity (primary endpoint) by the use of protons. the oncological non-inferiority of hypofractionated radiotherapy after surgery is a secondary endpoint.


Eligibility criteria:
inclusion criteria: * histology-proven prostate cancer with gleason score and psa-value; * indication for prostate bed irradiation (adjuvant/ salvage) after prostatectomy; * karnofsky-index ≥ 70% * age ≥ 18 years exclusion criteria: * androgen deprivation therapy * lymphatic spread * macroscopic tumor/ r2 * stage iv (m1) * previous irradiation
the effect of olive leaf extract administration on cardiovascular health

Conditions: Overweight and Obesity; Elevated Cholesterol

Summary: the purpose of this study is to investigate the effects of daily supplementation of olecol for a period of 8 weeks on cardiovascular risk markers.


Eligibility criteria:
inclusion criteria: * healthy individuals * age between 18 and 70 years * total cholesterol levels ≥ 5.0 mmol/l * bmi 25-35 kg/m2 exclusion criteria: * history of severe cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematological/immunologic, heent (head, ears, eyes, nose, throat). dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological diseases, allergy, major surgery and /or laboratory assessments that might limit participation in or completion of the study protocol. * diabetes * use of medication that might have influence on endpoints (e.g. cholesterol lowering medication, hypertension medication) * administration of investigational drugs or participation in any scientific intervention study which may interfere with this study in the 180 days prior to the study * use of antibiotics in the 30 days prior to the start of the study * use of antioxidants, minerals and vitamin supplements available in pharmacies, drugstores, food markets or in alternative medicine * pregnancy, lactation * abuse of products (\> 20 alcoholic consumptions per week and drugs) * smoking * weight gain or loss (\> 3 kg in previous 3 months) * high physical activity (\>4.5 hours of running/week) * history of any side effects towards intake of olives

Keywords: olive leaf extract cardiovascular health cholesterol